ACTRN12619000460101尚未招募2 期
A Prospective Comparison of 18F-PSMA-1007 and 68Ga-PSMA-11, using PET-CT, in primary and suspected recurrent Prostate Cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Diagnosis
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- Male
入选标准
- •1)be >= 18 years of age
- •2)have a confirmed diagnosis of prostate cancer from:
- •a)a biopsy-confirmed diagnosis of prostate cancer;
- •b)suspected recurrent prostate cancer after primary treatment; there is no study-specific PSA threshold value for biochemical recurrence, but rather the assessment of suspected recurrence is left to the referring Dr;
- •3)have a management question, for which a PSMA PET-CT scan is indicated and,
- •4)be willing to have two PET-CT scans on separate days.
排除标准
- •1)unable to provide written informed consent for the study and,
- •2)unable to lie flat for the scans
研究者
相似试验
进行中（未招募）
1 期
Comparative study of a specific imaging biomarker, 68Ga-PSMA-11, and the standard imaging protocol with 18F-Fluorocholine in the detection of Recurrence in Prostate Cancer PatientsMedDRA version: 20.0 Level: PT Classification code 10036911 Term: Prostate cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10066489 Term: Progression of prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10036917 Term: Prostate cancer stage I System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10036918 Term: Prostate cancer stage II System Organ Class: 10029104 - Neoplasms benign, malignant and unspProstate CancerEUCTR2016-003740-36-PTICNAS Produção Lda.46
进行中（未招募）
1 期
Comparison of 2 Imaging Tracers in Positron Emission Tomography for patients with prostate cancerSuspicion of prostate cancer recurrence after previous definitive treatment, based on American Society for Radiation Oncology (ASTRO) criteria of 3 consecutive PSA rises and/or ASTRO/Phoenix criteria of PSA nadir above 2.0 ng/mL afterradiotherapy or cryotherapy and/or greater than 0.2 ng/mL after prostatectomyMedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10036911Term: Prostate cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-002975-16-FRABX GmbH188
已完成
不适用
Head-to-head Comparison of 68Ga-PSMA-11 and 18F-PSMA-1007Prostate CancerNCT05079828Insel Gruppe AG, University Hospital Bern100
已完成
3 期
F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical RecurrenceProstate Cancer RecurrentProstate CancerNCT04102553ABX advanced biochemical compounds GmbH200
已完成
不适用
Genesis GBM 001 Phase I/II study of 68Ga-PSMA as a tumour targeting agent in relapsed glioblastomaBrain CancerGlioblastomaBrain CancerCancer - BrainGlioblastomaACTRN12618001346268Genesis Care11